Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, ...

Vertex Pharmaceuticals today announced that Health Canada has granted Marketing Authorization for PrALYFTREKTM (vanzacaftor/tezacaftor/deutivacaftor), a new triple combination therapy for patients ...

Vertex Pharmaceuticals has announced a broad reimbursement agreement with NHS England for ALYFTREK ...

Latest studies show Us pharma giant Vertex's new CF wonder pill Alyftrek has shown better results than their currently ...

NHS England » NHS to roll-out new ‘triple combination’ therapy for hundreds of children and adults with cystic fibrosis ...

The NHS will offer a once-daily triple therapy for cystic fibrosis to hundreds more patients, including those with rare ...

Reimbursement authority NICE has backed routine NHS use of Vertex's once-daily triple therapy Alyftrek ...

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) therapy has been recommended by the National Institute for ...

The new pill is seen as a ‘major leap forward’ for hundreds of patients living with the rarest forms of cystic fibrosis ...

Prof David Sheppard, Professor of Physiology, University of Bristol, said: ...

NHS patients in England with cystic fibrosis will be among the first in Europe to access a new treatment for their condition, ...